The prospective use of CRISPR-based gene editing has entered a new era with last year’s approval of CRISPR Therapeutics’/Vertex Pharmaceutical’s Casgevy (exagamglogene autotemcel) in key markets, laying down the groundwork for new approaches that use the technology to treat different diseases.
However, perhaps more than ever before, safety remains a key consideration for the space as companies continue pushing different approaches...